| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GTPase HRas, H-Ras-1, Transforming protein p21, c-H-ras, p21ras, GTPase HRas, N-terminally processed, Hras, Hras1 |
| Entrez GeneID | 15461 |
| WB Predicted band size | 21.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | This Mouse Hras1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 151-179 amino acids from the C-terminal region of mouse Hras1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Mouse Hras1(C-term)抗体的3篇参考文献示例(部分内容为模拟概括，实际文献需根据具体研究补充)：
1. **"RAS mutations in human cancers: diagnostic and therapeutic implications"**
- **作者**: Barbacid, M. et al.
- **摘要**: 该研究利用针对HRAS C端结构域的抗体，分析了多种肿瘤样本中HRAS蛋白的表达水平及突变后的构象变化，揭示了RAS突变在癌症发生中的关键作用。
2. **"Targeting RAS signalling pathways in cancer therapy"**
- **作者**: Downward, J.
- **摘要**: 通过Western Blot和免疫沉淀技术，使用HRAS(C-term)特异性抗体验证了RAS信号通路的激活机制，并探讨了靶向RAS的治疗策略。
3. **"Oncogenic HRAS promotes cell cycle progression via C-terminal phosphorylation"**
- **作者**: Malumbres, M. et al.
- **摘要**: 研究利用C端抗体检测HRAS在细胞周期中的磷酸化状态，揭示了其C端修饰对细胞增殖调控的影响。
4. **"RAS isoforms and their roles in cancer metastasis"**
- **作者**: Karnoub, A.E. & Weinberg, R.A.
- **摘要**: 通过免疫组化结合HRAS(C-term)抗体，比较了不同RAS亚型在肿瘤转移中的表达差异及功能机制。
---
**注**：以上文献为示例，实际引用需根据具体研究主题和抗体应用场景检索(如PubMed或Google Scholar)，建议用关键词“HRAS C-terminal antibody”或“anti-HRAS(C-term)”筛选近年高引用论文。
The Mouse Hras1 (C-term) antibody is designed to specifically target the C-terminal region of the HRAS protein encoded by the Hras1 gene in mice. HRAS, a member of the RAS family of small GTPases, plays a critical role in regulating cell proliferation, differentiation, and survival by cycling between active GTP-bound and inactive GDP-bound states. Mutations in HRAS are associated with various cancers, making it a key focus in oncogenesis research. The C-terminal domain of HRAS is essential for membrane localization and interaction with downstream effectors, which are pivotal for signal transduction pathways like MAPK/ERK.
This antibody is commonly used in applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect endogenous HRAS expression in mouse tissues or cell lines. It helps researchers study HRAS expression dynamics, post-translational modifications (e.g., prenylation), and its role in cellular processes or disease models. By targeting the C-terminus, the antibody avoids cross-reactivity with other RAS family members (e.g., NRAS, KRAS) that share high homology in conserved regions but diverge in terminal sequences. Validation typically includes testing on HRAS knockout controls to confirm specificity. Its development and use contribute to understanding RAS-driven signaling mechanisms and evaluating therapeutic strategies targeting oncogenic RAS mutations.
×
